Market Intelligence
Healthcare Artificial Intelligence Germany

Germany AI Healthcare Market

Executive Summary

With an increase of approximately 7.7% in total health expenditures from EUR 538.2 billion in 2024 to EUR 579.5 billion in 2025, Germany represents one of Europe’s largest healthcare markets by total spending, number of medical technology manufacturers and patient volume. Health insurance, whether statutory or private, is mandatory in Germany, which means that more than 60% of total healthcare spending in Germany is covered by insurers. It is estimated that by 2035, approximately 27.4% of the German population will be 65 years of age or older.  

The demand for AI-powered tools and systems to address the rising demand for healthcare services and products is increasing significantly. The AI-in-healthcare segment in Germany surpassed USD 410 million in 2025 and is estimated to grow to approximately USD 5 billion by 2034, which leads to a CAGR of approximately 31%. At an integration rate of 52.8%, AI is already widely implemented across healthcare processes and organizations in the German healthcare sector, which puts Germany ahead of other European countries like Spain, but leaves room for improvement situating Germany in the international midfield.

These factors make Germany one of the most influential healthcare markets in Europe and create opportunities for U.S. companies to engage in the German healthcare market and contribute to its ongoing transformation. Against this backdrop, AI-powered applications, hospital modernization and AI documentation, data analytics, interoperability services, computing, cloud storage and infrastructure as well as AI-supported clinical trials and research are major areas of opportunity for U.S. companies to enter the German market.

Market Landscape

Germany has already established regulatory and digital frameworks that enable adoption and scaling of AI products and services. Several reforms in recent years illustrate how eager the German market is for solutions to address growing needs and demand. The HealthID, which is currently used by 4.5 million patients, has been funded by health insurance funds since January 2024. There are 59 digital health applications (DiGAs) that are reimbursed and are meant to further accelerate the digitalization of the German healthcare sector. Germany’s aging population is further contributing to the rapid integration of AI into processes.  

The Health Data Utilization Act (GDNG) and Health Data Lab/FDZ (Forschungsdatenzentrum der Gesundheit) – a public data center - in Germany pave the legal way for secondary use of health data for research purposes as of 2024. This enables the training of AI software on real anonymized datasets and research carried out by pharmaceutical companies, med-tech firms, and scientific research institutions.

The Digital Act mandates electronic patient records (ePA) with an opt-out option for individuals and is a major step towards the digitalization of all patient records. Since January 2026, hospitals, doctors, and healthcare providers have been required to use ePA compatible software or risk being sanctioned by losing billing privileges.

Since February 2026, the “Digital Together 2026” strategy pursues the transformation of patient data transmission to electronic transmission. Additionally, more than 300 research projects that use data from the Health Data Lab are scheduled to be initiated. To help with this, the EUR 50 billion Transformation Fund launched in 2026 (2026-2035) will finance structural and IT upgrades to existing systems.

Isolated pilot projects are developing into systematic use and integration of AI-powered systems, offering opportunities for U.S. companies specializing in scalable, compliant solutions for building up Germany’s national digital infrastructure. Taken together, these reforms indicate areas of demand and opportunities for market entry.  

Opportunities for U.S. Companies

The main areas of interest to U.S. companies in the German AI-in-healthcare market are reimbursable digital applications, AI-powered and cloud-stored hospital documentation and infrastructure, data analytics and AI-enhanced clinical research and computing. The main point of entry for U.S. companies is the DiGA framework, with applications and digital offers, like therapy, that can be reimbursed. The goal here is to not only invest in developing applications, but to embed wider AI-powered healthcare monitoring and treatment tools for disease management, like diabetes within the DiGA framework. Providing AI-powered decision tools presents another scalable market potential for U.S. companies, under the condition that they are compliant with European Union (EU) and General Data Protection Regulation (GDPR) regulations. With the Digital Act’s extension to class IIb medical devices, telemonitoring solutions can now be reimbursed, which makes their implementation into practice much more attractive for German healthcare providers and increases the demand for such devices. To ensure successful market entry, U.S. companies should aim for integration with the HealthID, which is already being used by 4.5 million patients.

Another commercial prospect for U.S. companies lies in Germany’s hospital digitalization strategy. By 2028, the German government aims to raise hospitals’ level of digital maturity by more than 35% and use AI in documentation in over 70% of hospitals and facilities. This creates a strong and growing need for AI-powered documentation software, storage and interoperability services.

Beyond hospital operations, the opening of Germany’s health data infrastructure creates a parallel opportunity for U.S. data analytics providers. Access to previously unavailable health data through the Health Data Lab requires data analytics, computing and software that can handle the evaluation of millions of patient information records. U.S. companies with experience in data integration and data management can help German hospitals manage data volume and exchange across healthcare organizations.  

Lastly, the recently introduced contractual clauses for clinical trials (Standardvertragsklauselverordnung) simplify agreements between sponsors and trial sites. This paves the way for U.S. biotech and med-tech companies to connect with Germany’s research ecosystem and to conduct AI-enhanced clinical trials, which significantly accelerates research.

For products and services to successfully enter the German market, they must be compliant with EU-regulations and integrate into the European Health Data Space. While this makes initial market entry more difficult, it also allows for more seamless expansion into other countries. Germany is considered a frontrunner in AI-driven, data-intense healthcare in Europe. Success in Germany increases U.S. companies’ credibility and signals quality to other European markets, facilitating further expansion.  

German Institutions and Initiatives

  • Gematik (National Digital health Agency in Berlin) is a government-owned agency responsible for Germany’s telematics infrastructure (TI), the HealthID, interoperability standards and ePA transitions.  
  • BfArM (Federal Institute for Drugs and Medical Devices in Bonn) is responsible for DiGA approval, the authorization of clinical trials and licensing.
  • Health Data Lab/FDZ is a public health research data center in Germany.
  • Helmholtz Munich – Institute of AI for Health (AIH) is a European hub for AI and machine learning in medicine.  
  • Hasso Plattner Institute (HPI) Digital Health Cluster organizes an annual forum where researchers, policymakers and AI companies meet.

European Frameworks and Initiatives

  • The EU AI Act is the world’s first comprehensive AI regulatory framework. AI-powered medical devices such as diagnostic software, tools and decision-support systems are classified as “high-risk” AI systems. The Act imposes transparency rules on most AI-powered systems from August 2026.17
  • The European Health Data Space (EHDS) is the EU’s first sector-specific data space and requires each member state to establish a “Health Data Access Body” (HDAP) and enables secure secondary use of health data.  
  • Horizon Europe is the EU’s primary research and innovation funding program. The 2025 call included funding for cancer treatment using generative AI, smart health and digital care models.  

Trade Shows Focusing on AI in Healthcare

  • Health.tech global summit in Basel, Switzerland is a startup and investor conference focusing on digital health, med-tech and AI.  
  • DMEA in Berlin is Europe’s largest digital-health exhibition, focusing on electronic health records and AI, featuring dedicated AI tracks, presentations on deep-learning models for disease surveillance, and AI-powered tools. 
  •  

U.S. DEPARTMENT OF COMMERCE, INTERNATIONAL TRADE ADMINISTRATION CONTACT INFORMATION

For additional information, please contact:

Ulrike Riegeler
Commercial Specialist 
U.S. Commercial Service 
Ulrike.Riegeler@trade.gov
+49 69 7535 3157 
Frankfurt, Germany